, Columnist
Tom Price Cracks the Drug-Price Negotiation Door
Trump's nominee and a new report give the industry more reason to worry.
This article is for subscribers only.
The Senate finance committee's grilling this week of Tom Price, President Trump's nominee to head the Department of Health and Human Services, offered the usual combination of artful dodging and tiny scraps of information.
But sifting through the mostly non-answers revealed one interesting exchange, where Price may have cracked the door a bit on new drug-pricing policy.